	entitlement as at the international tiling	in relation to the international application No. PCT/EP2004/052029
	Name:	JANSSEN PHARMACEUTICA N.V.
		is entitled to claim priority of earlier application No. PCT/EP03/10263 by virtue of the following:
VIII-3-1(i i)		JANSSEN PHARMACEUTICA N.V. is entitled as employer of the inventor, SMANS, Karine, Alfonsine, Astrid
	This declaration is made for the purposes of:	all designations

	Declaration: Inventorship (only for	
	the purposes of the designation of	
	the United States of America) Declaration of Inventorship (Rules	
ŀ	4.17(iv) and 51bis.1(a)(iv)) for the	I hereby declare that I believe I am the
	purposes of the designation of the	original, first and sole (if only one
ľ	United States of America:	inventor is listed below) or joint (if
<b>!</b>		more than one inventor is listed below)
-		inventor of the subject matter which is
ì		claimed and for which a patent is
		sought.
		This declaration is directed to
ł		international application PCT/
		EP2004/052029 (if furnishing declaration
j		pursuant to Rule 26ter).
1		I hereby declare that my residence,
		mailing address, and citizenship are as
į		stated next to my name.
		<del>-</del>
		I hereby state that I have reviewed and understand the contents of the above-
		identified international application,
		including the claims of said
		application. I have identified in the
		request of said application, in
		compliance with PCT Rule 4.10, any claim
		to foreign priority, and I have
		identified below, under the heading
		"Prior Applications", by application
	¥	number, country or Member of the World
		Trade Organization, day, month, and year
		of filing, any application for a patent
		or inventor's certificate filed in a
		country other than the United States of
		America, including any PCT international
		application designating at least one
		country other than the United States of
		America, having a filing date before
		that of the application on which foreign
		priority is claimed.
VIII-4-1	Prior applications:	PCT/EP03/10263, EP, 12 September 2003
1	i noi applications.	(12.09.2003)
		[(32.03.2003)

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

VIII-4-1- Name (LAST, First) 1-1 VIII-4-1-Residence: (city and either US State, if applicable, VIII-4-1- Mailing address: 1-3 VIII-4-1- Citizenship: 1-4 VIII-4-1-Inventor's Signature: (if not contained in the request, or if 1-5 declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent) VIII-4-1-Date: (of signature which is not contained in 1-6

application)

the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international SMANS, Karine, Alfonsine, Astrid

2610 Wilrijk, Belgium

Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium

/Smans Karine/

06 September 2004 (06.09.2004)

VIII-4-1- 2-1	Name (LAST, First)	GIJSEN, Henricus, Jacobus, Maria
2-2	Residence: (city and either US State, if applicable, or country)	4813 XC Breda, Netherlands
VIII-4-1- 2-3	Mailing address:	Janssen Pharmaceutica N.V. Turnhoutseweg 30 B-2340 Beerse Belgium
VIII-4-1- 2-4	Citizenship:	NL
VIII-4-1- 2-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	/Gijsen, Henricus/
VIII-4-1- 2-6	_ ,	06 September 2004 (06.09.2004)